Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

Principal Investigator: Niu, Alex

A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Principal Investigator: Wang, Eunice S

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors

Principal Investigator: Fountzilas, Christos

B-Adrenergic Blockade with Chemotherapy and Checkpoint Inhibition in PD-L1
Positive Metastatic Triple Negative Breast Cancer

Principal Investigator: Kabraji, Sheheryar K

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Principal Investigator: Cortese, Matthew J

A scalable cruciferous vegetable intervention to reduce bladder cancer recurrence and progression

Principal Investigator: Yeary, Karen H

(A012301) LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

Principal Investigator: Levine, Ellis G

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients with Relapsed or Refractory Multiple Myeloma (MM) with Extramedullary Disease (EMD)

Principal Investigator: Hillengass, Jens

(AREN1921) Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Principal Investigator: Twist, Clare J

Randomized Phase 2 Study: Neoadjuvant conditioning of prostate cancer tumor microenvironment using a novel chemokine-modulating regimen

Principal Investigator: Chatta, Gurkamal S

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic…

Principal Investigator: Thompson, J

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Principal Investigator: Mager, Katherine

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Principal Investigator: Malek, Ehsan

A Phase 1, First-in-Human, Open-Label, DoseEscalation and Expansion Study of IMGN151 (anti-FR-alpha antibody drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers

Principal Investigator: Zsiros, Emese

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Principal Investigator: Fountzilas, Christos

A FIRST-IN-HUMAN PHASE 1/2 OPEN-LABEL STUDY OF INTRAVENOUS ST 067, SUBCUTANEOUS ST-067 WITH OR WITHOUT OBINUTUZUMAB PRE TREATMENT, AND ST-067 IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES

Principal Investigator: Puzanov, Igor

Financial Compass: A Pilot Feasibility Study of a Novel Intervention to Identify and Address Financial Hardship among Cancer Patients

Principal Investigator: Bouchard, Elizabeth G

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)

Principal Investigator: Switzer, Benjamin J

Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination with Other Antitumor Agents in Participants with Advanced Malignancies Driven by the MAPK Pathway

Principal Investigator: Jain, Prantesh

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

Principal Investigator: Bouchard, Elizabeth G

MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication Adherence

Principal Investigator: Kelly, Kara M

I Can Join the Fight Against Cancer: An intervention to programmatically build grassroots actions to reduce the cancer burden.

Principal Investigator: Bouchard, Elizabeth G

Addressing Disparities in Breast Cancer Care: An approach to health equity

Principal Investigator: Glaser, Kathryn M

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Principal Investigator: Zsiros, Emese